Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.

The symposium highlighted the importance of genetics in understanding and treating complex skin diseases.

Combination therapies might work better for some vitiligo patients, but results vary.

Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.

Topical corticosteroids are the best initial treatment for children with Alopecia Areata.

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.

Baricitinib may effectively treat oral lichen planus.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Three compounds from Dadap leaves may help treat hair loss.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Tofacitinib may help treat severe hair loss, but more research is needed.